about
Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems.Interactions of Pluronic nanocarriers with 2D and 3D cell cultures: Effects of PEO block length and aggregation state.Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells.Experimental design towards an optimal lipid nanosystem: a new opportunity for paclitaxel-based therapeutics.Cytotoxicity and internalization of Pluronic micelles stabilized by core cross-linking.Lack of a unique kinetic pathway in the growth and decay of Pluronic micelles.Fate of Organic Functionalities Conjugated to Theranostic Nanoparticles upon Their Activation.
P50
Q38170904-401C002C-2E8B-4B30-9964-00447FEFFB6DQ38801209-1D8E07A2-5FBA-4A51-8FB4-2754165308ABQ38846958-D7061001-B163-46E3-AC64-FC8DECFBC5D4Q39175779-8D7D8850-3C58-4ACE-9BEA-A55AC034777CQ42834535-D7946869-C949-4719-85A3-271250677167Q53292468-7888F953-B558-49EF-826C-BCE8AB97A29EQ53399887-286018D9-2DF5-41E1-A779-5DACEFC07BB9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexandra Arranja
@ast
Alexandra Arranja
@en
Alexandra Arranja
@es
Alexandra Arranja
@nl
type
label
Alexandra Arranja
@ast
Alexandra Arranja
@en
Alexandra Arranja
@es
Alexandra Arranja
@nl
prefLabel
Alexandra Arranja
@ast
Alexandra Arranja
@en
Alexandra Arranja
@es
Alexandra Arranja
@nl
P106
P1153
55981561200
P21
P31
P496
0000-0002-5613-6084